diabetic foot syndromeOXYMED Center has created new programme OxyDia, which focuses on patients with diabetic foot syndrome

Programme OxyDia was specifically created for the patients diagnosed with the diabetic foot syndrome to enable them to access an extremely effective therapeutic method at the OXYMED Center. There is substantial, peer-reviewed, medical evidence that HBOT accelerates the healing process, significantly reducing the risk of amputation (up to 50%) and can shorten the duration of treatment.  It also increases the number of diabetic wounds healed completely in the long run. There are even a number of medical studies that have shown therapeutic and economic effect of the use of HBO in diabetic foot syndrome.

At the center, we consider the health of the patients of the utmost importance and our ultimate goal is to improve their quality of life. The patients who enrol in the OxyDia Programme are assigned to teams of specialized doctors from the fields of diabetology, surgery, angiology, internal medicine and anaesthesiology that will provide professional expertise at the center and supervise the therapy sessions.

Dr. Kalinová Slavka, M.D.Department of Diabetology

Dr. Pamulla Marian, M.D. Department of Surgery

Dr. Fašang Milan, M.D. Department of Internal Medicine and Anaesthesiology

The partner of this project is non-investment fund association Cukrovka (Diabetes)

The purpose of the non-investment fund association Cukrovka (Diabetes) is to bring together financial funds that aim to fulfil goals that are beneficial to the general public in the field of health protection and prevention, education, research and development, with a particular focus on: contributions to purchasing of medical devices, diagnostic tools, equipment and materials related to the protection and promotion of health and education, support of research and development of new medical devices, diagnostic tools, equipment and materials, financial support for various forms of education, purchase of literature and support of exchange and therapy visits.

What is diabetic foot?


Diabetic foot is a pathological condition arising due to diabetes mellitus by disrupting the tissue on the foot. The severe consequences of diabetic foot syndrome include ulcerations, gangrenes (20 times more likely than in healthy people) and amputations (30 times more often than in healthy people). Around 20% of diabetics suffer from the diabetic foot syndrome.

There are an estimated 336,000 diabetics in Slovakia, out of which about 30,000 to 45,000 suffer from the diabetic foot syndrome. There are around 2,000 amputations carried out on average each year among these patients.

HBOT in the treatment process of diabetic foot

The hyperbaric oxygen therapy represents an important part in the treatment of diabetic foot within the medical practice.

Hyperbaric oxygen therapy – breathing 100% oxygen under pressure higher than the atmospheric one – increases tissue oxygenation in the hypo-perfused area (with poor blood circulation) of the ulcer, which is ​​ischemic due to infection as well. Hyperbaric oxygen promotes the formation of collagen, revascularization (restoring blood tissue) and increases the activity of leukocytes.

A prerequisite for successful healing is good glycaemic control, leg relief, removing pressure from the ulceration, appropriate antibiotic therapy against the infection according to culture and sensitivity of bacterial flora, and local therapy, consisting of mechanical debridement of the wound, and promotion of granulation and epithelisation (emergence of new tissue lineage in the damaged area).

The invasive vascular reconstruction is of great importance in the treatment as well, for example the percutaneous transluminal angioplasty.

OxyDia Programme

Frequent and clinically easiest to diagnose is the symptom of the disability in lower limbs, which is called the diabetic foot syndrome in medical practice. This syndrome is caused by several pathological pathways which operate on the basis of the underlying disease – Diabetes mellitus.


  • Macroangiopathy
  • Microangiopathy
  • Neuropathy
  • Subsequent, resulting bacterial infection of the damaged tissue

These pathological mechanisms lead to a painful picture of the disease of lower extremities, which, in many cases, result in amputation of the lower limb.

Treatment of Diabetic Foot Syndrome with HBOT

The therapeutic effects of hyperbaric oxygen (HBO) reduce the number of amputations themselves. HBO has a positive effect on this disease via multiple factors.

Treatment goal is achieved by a combination of the following effects:
  • Correction of tissue hypoxia by increasing the oxygen content in the blood plasma
  • Redirection of the blood flow to hypoxic areas
  • Improvement of microcirculation by increasing the elasticity of erythrocytes
  • Reduction of swelling of the wound
  • Increase of the absorption of microorganisms by the white blood cells
  • Direct toxic effect on several species of bacteria
  • Stimulation and creation new blood vessels
  • Activation of elements for wound healing

Treatment with hyperbaric chamber is not only effective, but economically viable as well

The 4th and the 8th European Consensus Conferences held in London in 1998 and in Ravel in 2006, respectively, were dedicated to the topic of assessing the effectiveness of HBOT in the treatment of diabetic foot. The importance of the use of HBOT for diabetic foot syndrome is also included in the meta-analysis within the world-renowned framework of the Cochrane Review. The conclusion was that for the patients with ulceration, the HBOT significantly reduces the high risk of amputation with a significant chance of complete healing within one year. Numerous studies have evaluated the cost of the treatment and after-care of patients with diabetic foot. A recent study published in the International Journal of Technology Assessment in Health Care presented results from Canada, assessing the cost of treatment in the twelve-year period for patients with and without the application of hyperbaric oxygen therapy. Cost savings for patients with HBOT was 10,000 Canadian dollars (circa 7,500 EUR).


Get the Facebook Likebox Slider Pro for WordPress